Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | TKT | P29401 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785253 | 0.80 | POLB (0.40) | UHRF1TKTAPLNRPOLB | |
| SCHEMBL17297734 | 0.78 | POLB (0.33) | UHRF1TKTPOLB | |
| SCHEMBL12447891 | 0.77 | APLNR (0.35) | TKTAPLNRNOS3NOS1NOS2 | |
| SCHEMBL2737354 | 0.77 | APLNR (0.35) | TKTAPLNR | |
| SCHEMBL10996190 | 0.77 | TKT (0.35) | UHRF1TKTAPLNRPOLB | |
| SCHEMBL5800504 | 0.77 | POLB (0.33) | UHRF1TKTPOLB | |
| SCHEMBL5779559 | 0.77 | POLB (0.33) | UHRF1TKTPOLB | |
| SCHEMBL14998951 | 0.74 | PTGS1 (0.35) | TKTAPLNRPOLB | |
| SCHEMBL21374860 | 0.74 | APLNR (0.33) | TKTAPLNR | |
| SCHEMBL25928371 | 0.74 | APLNR (0.33) | TKTAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | UHRF1 302/4885TKT 2526/4885APLNR 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.